<DOC>
	<DOCNO>NCT00626249</DOCNO>
	<brief_summary>24 diabetic mild &amp; moderate renal disease 12 diabetic without renal disease . One screening , one dosing &amp; one follow-up visit TechnosphereÂ® Inhalation Powder give Visit 2 via MedToneÂ® Inhaler PK test 26 designated time point</brief_summary>
	<brief_title>Single Dose , Single Administration Study Technosphere Inhalation Powder Diabetic Subjects With Mild Moderate Kidney Disease Compared Diabetic Subjects With Normal Kidney Function</brief_title>
	<detailed_description>This Phase 1 , single-dose trial conduct determine nephropathy affect way kidney eliminate byproduct TechnosphereÂ® Inhalation Powder compare kidney free disease . This trial test safety , tolerability pharmacokinetics study medication . The trial consist screen , dose follow-up visit . Single dose administration TechnosphereÂ® Inhalation Powder occur dose visit . ( V2 ) serum urine PK testing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Nonsmoking male female , = 18 = 80 year BMI = 37 kg/m2 Type 1 type 2 diabetic Subjects mild moderate DNP subject normal renal function , base GFR rate albuminuria Normal pulmonary function performance base PFTs No history COPD , asthma , active respiratory infection ; must able perform PFTs No dose and/or formulation change within precede 6 week concomitant medication No clinically significant major organ/systemic disease No previous current chemotherapy radiation therapy may result pulmonary toxicity No clinically significant abnormality screen laboratory evaluation , except abnormal laboratory renal parameter subject DNP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Nephropathy</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Renal</keyword>
	<keyword>Diabetics</keyword>
</DOC>